Wolfe Research stays Peerperform on Sarepta Therapeutics (SRPT) as data boosts RNA-focused narrative
March 25, 2026 10:43 AM
Wolfe Research analyst Andy Chen reiterated a Peerperform rating on Sarepta Therapeutics (NASDAQ: SRPT)The analyst commented, "Limited data but company ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
